Non-myeloablative bone marrow transplantation in an adult with Wiskott-Aldrich syndrome

Br J Haematol. 2002 Feb;116(2):497-9. doi: 10.1046/j.1365-2141.2002.03269.x.

Abstract

Early bone marrow transplant is now standard treatment for infants with severe immunodeficiencies such as Wiskott-Aldrich Syndrome (WAS), but results in older children and adults are poor. Non-myeloablative transplant has shown promise in the treatment of older children, who are likely to have active infections and organ damage. We describe a non-myeloablative transplant of a 26-year-old man with WAS, undertaken because of severe infections and vasculitis. Partial engraftment and immunorestoration were achieved. The patient is well 1 year post transplantation.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Alemtuzumab
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use
  • Bone Marrow Transplantation / methods*
  • Cyclophosphamide / therapeutic use
  • Humans
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Penicillin V / administration & dosage
  • Transplantation Chimera
  • Trimethoprim, Sulfamethoxazole Drug Combination / administration & dosage
  • Vidarabine / analogs & derivatives
  • Vidarabine / therapeutic use
  • Wiskott-Aldrich Syndrome / therapy*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Immunoglobulins, Intravenous
  • Immunosuppressive Agents
  • Alemtuzumab
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Cyclophosphamide
  • Vidarabine
  • fludarabine
  • Penicillin V